Shanghai Pharmaceuticals Holding Co., Ltd
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SHPMY | X2S.F | GU5.F | 600511.SS | 600056.SS | 600998.SS | |
|---|---|---|---|---|---|---|
| Market cap | 5.26B | 5.94B | 2.36B | 21.87B | 13.54B | 26.47B |
| P/E (TTM) | 7.0 | 6.8 | 8.5 | 11.1 | 43.1 | 13.8 |
| Forward P/E | — | — | — | 10.3 | 5.2 | 12.1 |
| Price/book | 0.4 | 0.5 | 0.5 | 1.1 | 1.1 | 0.9 |
| Dividend yield | 4.68% | 4.63% | 6.66% | 2.77% | 1.05% | 3.75% |
| 1-year change | −13.85% | −12.64% | −30.48% | −2.40% | −19.66% | +4.91% |
| Today | 0.00% | −0.88% | −0.68% | +0.28% | +0.22% | −1.69% |
The closest companies by business and industry (Medical Distribution). Prices may be delayed up to 15 min.
Latest news
All SHPMY news ›Application Cases of Wastewater Discharge Outlets in Shanghai's Pharmaceutical Industry
Pudong Shanghai China October 13 2026 A biopharmaceutical company based in Shanghai engaged in technical research within the field of biological products as well as the production and processing of laboratory reagents intermediates…
China's Shanghai Pharmaceuticals wins production approval for clevidipine injectable emulsion; R&D spend hits 52.2 million yuan
Shanghai Pharmaceuticals' subsidiary SPH No.1 Biochemical & Pharmaceutical has received a Drug Registration Certificate from China's National Medical Products Administration for clevidipine injectable emulsion, clearing the drug for…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- finance.biggo.com1
- openpr.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.